SparingVision Conference Participation in H2 2025 Paris, 2 July 2025 – SparingVision (“the Company”),…

Keep up to date with all of our latest news.

SparingVision Conference Participation in H2 2025
SparingVision Conference Participation in H2 2025 Paris, 2 July 2025 – SparingVision (“the Company”),…
SparingVision appoints Dr. Kali Stasi as Chief Medical Officer
SparingVision appoints Dr. Kali Stasi as Chief Medical Officer Experienced global leader in ophthalmology…
SparingVision Presents PRODYGY data and Research Update in Two Oral Presentations at ASGCT 2025
SparingVision Presents PRODYGY data and Research Update in Two Oral Presentations at ASGCT 2025 Favorable…
SparingVision Announces Favorable Safety Update from PRODYGY Trial at ARVO 2025
SparingVision Announces Favorable Safety Update from PRODYGY Trial at ARVO 2025 Preliminary safety data…
SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary to Dry-AMD
SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary…
SparingVision to Highlight Progress of its Gene Therapy Programs at ARVO and ASGCT 2025
SparingVision to Highlight Progress of its Gene Therapy Programs at ARVO and ASGCT 2025 Paris,…
SparingVision appoints Anjeza Gjino as Chief Financial Officer
SparingVision appoints Anjeza Gjino as Chief Financial Officer Paris, 3 March, 2025 – SparingVision (“the…